Insufficient SARS-CoV-2 testing has left many nations flying blind as they reopen their economies. Without adequate testing, new infections could outrun control measures.
COVID-19 has laid bare the weaknesses of clinical diagnostics infrastructures. Underfunded, undervalued and underprepared, laboratory testing has been overwhelmed by the contagion. A combination of low reimbursement, low margins, low capacity and low investment has stifled innovation and competition. Cost-cutting, centralization and regulatory rigidity have created backlogs and slowed the tracking of infections. Given the pivotal role of diagnostics in healthcare decision-making, COVID-19 shows just how much clinical testing needs a radical rethink.
Nature Biotechnology volume 38, page653,